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Zusammenfassung  III 
Zusammenfassung 
Kardiovaskuläre Erkrankungen weisen die höchste Sterblichkeitsrate in der westlichen 
Welt auf. Zu ihnen gehören viele verschiedene Krankheiten, wie z.B. die koronare 
Herzkrankheit (KHK). Der Hauptauslöser für die Entwicklung dieser Erkrankungen ist 
die Atherosklerose. Sie ist ein fortschreitender, entzündlicher Prozess, bei dem eine 
Verengung der Arterien durch die Bildung von atherosklerotischen Plaques auftritt. 
Dadurch kann weniger Blut zum Herzen transportiert werden, was zu einer generellen 
Unterversorgung des Herzmuskels oder im schlimmsten Fall zu einem Myokardinfarkt 
führen kann. Um den natürlichen Blutfluss in dem verengten Abschnitt der Arterie 
wiederherzustellen, sind zwei interventionelle Therapieoptionen üblich: 1) die 
Koronararterien-Bypass-Operation (CABG) oder 2) die perkutane transluminale 
Koronarangioplastie (PTCA). Während bei der CABG überwiegend autologe 
Venentransplantate verwendet werden, wird bei der PTCA ein Ballon für die 
Erweiterung der Arterie verwendet, mit der Option, einen Stent über den Katheter zu 
platzieren. Beim Einbringen der bisher üblichen Stents, wie Bare Metal Stents (BMS) 
oder Drug Eluting Stents (DES), kann das Endothel durch das Expandieren des Stents 
und durch dessen Drahtgeflecht geschädigt werden und es kann zu einer 
nachfolgenden Entzündungsreaktion und einem Wiederverschluss (Restenose) 
kommen. Mit den DES wird dieses Risiko minimiert, da sie antiproliferative oder 
immunsuppressive Wirkstoffe freisetzen. Jedoch birgt dieser Vorteil auch einen 
Nachteil, da die Wirkstoffe gleichzeitig das Wachstum von Endothelzellen hemmen 
und Patienten länger auf antithrombotische Medikamente angewiesen sind. 
Gegenwärtig gibt es viele verschiedene Ansätze zur Entwicklung von Stents der 
nächsten Generation, um unerwünschte Reaktionen wie die In-Stent-Restenose (ISR) 
und eine späte Stentthrombose zu verringern. 
Ein initialer Prozess während der Entwicklung der Atherosklerose und nach Verletzung 
des arteriellen Gewebes durch die Stent-Implantation ist die Rekrutierung von 
Leukozyten. Diese wird durch verschiedene zelluläre Adhäsionsmoleküle (CAMs) wie 
z. B. dem interzellulären Adhäsionsmolekül 1 (ICAM–1), welches im Bereich der 
Verletzung von Endothelzellen vermehrt gebildet wird, vermittelt. ICAM–1 gehört zur 
sogenannten Leukozytenadhäsionsmolekülkaskade. 
Wenn es möglich wäre die Bildung des ICAM–1 sowie die Bildung weiterer relevanter 
Proteine spezifisch durch siRNA zu hemmen, so könnte die initiale 
Leukozytenadhäsionsmolekülkaskade durchbrochen und die Restenosegefahr 
vermindert werden. 
Drei verschiedene Stent-Beschichtungssysteme zur substratvermittelten small 
interfering RNA (siRNA)-Freisetzung gegen ICAM–1 wurden in dieser Arbeit 
entwickelt. Als Basis für die Schichtsysteme dienten Lipoplexe aus 
Lipofectamine®2000 und spezifische sowie fluoreszenzmarkierte siRNA oder 
Polyplexe aus Poly(ethylenimin) (PEI) und siRNA. Als Biomaterialien für die Einbettung 
der Lipo- oder Polyplexe wurden Atelokollagen, verschiedene Poly(lactid-co-glycolid) 
(PLGA) Resomere oder Polyelektrolyt-Mehrschicht (PEM)-Schichtsysteme aus PEI 
und Hyaluronsäure (HA) verwendet. Die Aufnahme bzw. Transfektion von siRNA in 
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Zellen der Zelllinie EA.hy926 konnte mit allen drei Stent-Beschichtungssystemen 
nachgewiesen werden. Darüber hinaus wurde untersucht, ob die Schichtsysteme über 
eine Langzeitfreisetzung verfügen oder die siRNA über einen kurzen Zeitraum 
abgeben. Die langfristige Freisetzung von siRNA ist besonders interessant für die 
Stent-Therapie, da der Stent in der Arterie verbleibt, um ihn offen zu halten, und die 
Heilung eines verletzten Endothels bis zu drei Monate dauern kann. 
Die erwünschte Langzeitfreisetzung von Lipoplexen, die in die PLGA-Beschichtungen 
eingebettet waren, konnte vom ersten bis zum zwanzigsten Tag gezeigt werden. Die 
etablierte Atelokollagen-Beschichtung mit siICAM–1-Lipoplexen bewirkte eine 
signifikante Reduktion der ICAM–1-Expression bis zum achten Tag. In beiden 
Ansätzen wurde die spezifische Spaltung der ICAM–1 messenger RNA (mRNA) 
gezeigt und eine gute Zellviabilität und Hämokompatibilität der Beschichtungen 
nachgewiesen. 
Der PLGA-Mehrschichtaufbau eignet sich außerdem zur simultanen Kotransfektion 
der grün fluoreszierenden (eGFP)mRNA und siRNA. Die beiden substratvermittelten 
siRNA-Freisetzungssysteme mit Langzeitwirkung ebnen den Weg für neue 
therapeutische Stentbeschichtungen, um das ISR-Risiko nach der Stentimplantation 
zu reduzieren. 
Das PEM-System mit HA und Polyplexen zeigte eine schnelle Freisetzung von siRNA-
Partikeln innerhalb der ersten Stunde. Eine signifikante Verringerung des ICAM–1 
Proteins wurde nachgewiesen und die Zellviabilität war nicht signifikant reduziert. 
Somit liefert diese Entwicklung ein weiteres lokales Anwendungssystem, das in die 
PTCA integriert werden kann. 
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Summary 
Cardiovascular diseases have the highest mortality rate in the western world. They 
include many different diseases, such as the coronary heart disease (CHD). The main 
trigger for the development of these diseases is atherosclerosis. It is a progressive, 
inflammatory process in which arterial narrowing occurs through the formation of 
atherosclerotic plaques. As a result, less blood can be transported to the heart, which 
can lead to a general undersupply of the heart muscle or in worst case to a myocardial 
infarction. To restore natural blood flow in the narrowed section of the artery, two 
interventional therapy options are common: 1) coronary artery bypass graft (CABG) or 
2) percutaneous transluminal coronary angioplasty (PTCA). While CABG uses 
predominantly autologous vein grafts, the PTCA uses a balloon to dilate the artery, 
with the option of placing a stent by catheter. When introducing conventional stents, 
such as bare metal stents (BMSs) or drug-eluting stents (DESs), the endothelium can 
be damaged by the expansion of the stent and its wire mesh, and a subsequent 
inflammatory reaction and re-occlusion (restenosis) can occur. DES minimizes this risk 
by releasing antiproliferative or immunosuppressant drugs. However, this advantage 
also has a disadvantage, since the active ingredients simultaneously inhibit the growth 
of endothelial cells and patients are more dependent on antithrombotic drugs. There 
are currently many different approaches to developing next-generation stents to 
minimize adverse reactions such as in-stent restenosis (ISR) and late stent 
thrombosis. 
An initial process is the recruitment of leukocytes during the development of 
atherosclerosis and after injury of the arterial tissue by the stent implantation. This is 
mediated by various cellular adhesion molecules (CAMs), such as the intercellular 
adhesion molecule 1 (ICAM–1), which is increasingly formed around injury to 
endothelial cells. ICAM–1 belongs to the so-called leukocyte adhesion molecule 
cascade. 
If it were possible to specifically inhibit the formation of ICAM–1 and the formation of 
other relevant proteins by siRNA, the initial leukocyte adhesion molecule cascade 
could be disrupted, and the risk of restenosis reduced. 
Three different stent coating systems for substrate-mediated siRNA release against 
ICAM–1 were developed in this work. Lipoplexes of Lipofectamine®2000 and specific 
and fluorescently labeled siRNA or polyplexes of poly (ethyleneimine) (PEI) and siRNA 
served as basis for the coating systems. As biomaterials for embedding the lipo- or 
polyplexes, atelocollagen (ATCOL), various poly (lactide-co-glycolide) (PLGA) 
resomers or polyelectrolyte multilayer (PEM) systems of PEI and hyaluronic acid (HA) 
have been used. The uptake or transfection of siRNA into cells of the cell line EA.hy926 
was detected with all three stent coating systems. In addition, it was investigated 
whether the layer systems have a sustained release or release the siRNA over a short 
period of time. The long-term release of siRNA is particularly interesting for stent 
therapy because the stent remains in the artery to keep it open, and the healing of an 
injured endothelium can take up to three months. 
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The desired sustained release of lipoplexes embedded in the PLGA coatings could be 
demonstrated from the first to the twentieth day. The established ATCOL coating with 
siICAM–1 lipoplexes resulted in a significant reduction in ICAM–1 expression until the 
eighth day. Both approaches demonstrated specific cleavage of the ICAM–1 
messenger RNA (mRNA) and demonstrated good cell viability and hemocompatibility 
of the coatings. 
The PLGA multilayer construction is also suitable for simultaneous co-transfection of 
green fluorescent (eGFP)mRNA and siRNA. The two long-acting substrate-mediated 
siRNA release systems pave the way for new therapeutic stent coatings to reduce ISR 
risk after stent placement. 
The HA and polyplex PEM system showed rapid release of siRNA particles within the 
first hour. Significant reduction of the ICAM–1 protein was demonstrated, and cell 
viability was not significantly reduced. Thus, this development provides another local 
application system that could be integrated into the PTCA. 
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1 Introduction 
1.1 Cardiovascular disease and the coronary heart disease 
Cardiovascular diseases (CVDs) claimed more than 17.7 million deaths in 2015 and 
are responsible for a death rate of 31% worldwide, leading the mortality statistics on 
global scale [1-3]. Within this group, there are different classifications of this disease, 
such as the coronary heart disease (CHD) where arterial vessels are affected that 
generally apply oxygen-rich blood to the myocardium. The occurrence of 
arteriosclerosis in the CHD causes a narrowing of the artery due to atherosclerotic 
plaques and a lower blood flow to the heart. As a result, the heart muscle is no longer 
sufficiently supplied with oxygen and nutrients and parts of it can die off resulting in the 
worst case in myocardial infarction [4]. The main risk factors for the development of an 
atherosclerosis are: hypertension, diabetes mellitus, hyperlipidemia, obesity, smoking, 
genetic abnormalities and lack of physical activity and should therefore be treated with 
preventive care [5, 6]. 
1.1.1 Atherosclerosis and its genesis 
Atherosclerosis represents the most common cause for CVD like CHD, coronary artery 
disease (CAD) and peripheral artery disease that are special types of arteriosclerosis. 
While arteriosclerosis describes the loss of elasticity of the large arteries, 
atherosclerosis is a progressive disease where an atherosclerotic plaque is formed by 
lipids and fibrous elements causing the hardening of the artery. Although not all factors 
of atherogenesis have been revealed, it is known that the morphology of the endothelial 
cells (ECs) and low-density lipoproteins (LDLs) play a major role in the initial step of 
vascular lesions. ECs in tubular regions with laminar blood flow have an ellipsoid shape 
and are aligned to the bloodstream. However, ECs in branching or curvature regions 
show polygonal undirected shape with a thin glycocalyx layer and are predominated 
for endothelial lesion [7, 8]. The spontaneous damage of the arterial endothelium due 
to turbulence blood flow, low fluid shear stress or other endothelial injuries leads to 
increased permeability for macromolecules [7, 9]. In this process, the two proteins 
endothelial nitric oxide synthase (eNOS) and superoxide dismutase (SOD) show 
reduced expression. Consequently, their reduction causes the retention of LDL via 
apolipoprotein B (apoB) leading to accumulation of LDL in the subendothelial layer, the 
tunica intima [10]. Generally, a normal nitric oxide (NO) level acts as a protector against 
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the development of atherosclerosis and inhibits platelet and leukocyte aggregation, 
prevents platelet, leukocyte and monocyte adhesion on the endothelium, and reduces 
vascular smooth muscle cell (VSMC) proliferation [11, 12]. Additionally, SOD is 
necessary for the cells to protect them against the superoxide anion radical [13]. One 
major cause for atherogenesis is the activation of endothelial cells via increased 
transcription factor NF-κB due to the oxidation of LDL by reactive oxygen or enzymes 
and the subsequent inflammatory processes [14, 15]. Oxidized LDL (oxLDL) 
accumulates in the subendothelial layer and stimulates the ECs to produce 
macrophage colony-stimulating factor (M-CSF), monocyte chemoattractant protein–1 
(MCP–1), and the increased expression of cellular adhesion molecules (CAMs) which 
attract leukocytes and platelets to the endothelium (exactly described in chapter 1.1.2) 
[16, 17]. After monocyte infiltration into subendothelial layer, M-CSF causes the 
phenotypically change into macrophages. The scavenger receptors, CD36, lectin-like 
receptor–1 (LOX–1) or CXCL16 on the macrophages are responsible for the 
internalization of the oxLDL leading to its accumulation and foam cell building of 
macrophages [18]. The ongoing formation of foam cells lead to fatty streaks in the 
tunica intima. Fatty streaks can appear in arteries in early life and can regress again, 
if foam cells do not recruit VSMCs ending up in advanced lesion. Different types of 
atherogenic cytokines or chemoattractants form foam cells. ECs and T-cells induce the 
migration and proliferation of the VSMCs from the tunica media to the intima and are 
responsible for intimal thickening (Figure 1) [19]. Here, phenotypic change of VSMCs 
causes expression of different receptors like scavenger receptors, CD36, and LOX–1 
for the uptake of oxLDL [20]. Additionally, VSMCs are responsible for vascular 
remodeling due to the production of extracellular matrix (ECM) proteins like collagen, 
proteoglycans, fibronectin and elastin and the formation of a fibrous cap protecting the 
underlying core of foam cells and necrotic tissue [18, 21]. Different cytokines of the 
ongoing inflammatory process destabilize the atherosclerotic plaque. The apoptosis of 
macrophages and foam cells causes an enlargement of the lipid core and the fibrous 
cap gets thinner due to VSMC death as well as the lack of stabilizing ECM proteins 
[19]. This thin layer of the fibrous cap can break up very easily in the arterial lumen and 
the thrombogenic lipid core, and its high amount of tissue factor are released [22]. The 
coagulation cascade starts and platelets react with adhesion and aggregation leading 
to thrombosis and consequently to clinical incidences like myocardial infarction or 
stroke [23, 24]. 
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Figure 1: The development of atherosclerosis. It begins with monocyte infiltration and leukocyte 
adhesion with diapedesis, followed by plaque formation, plaque rupture and ends with the formation of 
a thrombus. Redesigned an inspired by the image of Libby et al., 2011 [25]. 
1.1.2 Cellular adhesion molecules and leukocyte adhesion cascade 
Tissue injury or inflammation is the trigger for the recruitment of leukocytes from the 
blood to the site of injury or inflammation where the immune response is needed for 
tissue repair. The leukocyte migration and the following diapedesis is targeted and 
controlled by proinflammatory cytokines that lead the leukocytes to the site of 
inflammation, so the surrounding healthy tissue is not attacked. The cytokines 
Interleukin–1 (IL–1), Interleukin–6 (IL–6), tumor necrosis factor-α (TNF-α) and 
chemokines are distributed and activate endothelial cells which react with increasingly 
expression of the CAMs like intercellular adhesion molecule–1 (ICAM–1), vascular cell 
adhesion molecule–1 (VCAM–1), P-selectin, and E-selectin [26, 27]. An important 
factor for the adhesion of leukocytes and platelets is the slowing down of the blood 
stream due to the inflammation, which simplifies their binding to the adhesion 
molecules. The leukocyte adhesion cascade is divided into three sections according to 
the original model: 1) selectin-mediated leukocyte rolling, 2) chemokine-mediated 
leukocyte activation, and 3) integrin-mediated leukocyte arrest [28] (Figure 2). 
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Figure 2: The leukocyte adhesion cascade during inflammation with leukocyte rolling, activation, 
arrest, and transmigration. ICAM–1 is marked in yellow because it is important for this thesis. Different 
selectins, chemokines, and integrins are involved in this process: PSGL–1: P-selectin glycoprotein 
ligand–1; VLA4: very late antigen 4; LFA1: lymphocyte function-associated antigen 1; MADCAM1: 
mucosal vascular addressin cell adhesion molecule 1; PI3K: phosphoinositide 3–kinase; MAC1: 
macrophage–1 antigen; VCAM–1: vascular cell adhesion molecule–1; ICAM–1: intercellular adhesion 
molecule–1; VCAM–1: vascular cell adhesion molecule–1; PECAM–1: platelet/endothelial-cell adhesion 
molecule–1; JAM: junctional adhesion molecule; ESAM: endothelial cell specific adhesion molecule. 
Adapted and modified from Ley et al., 2007 [29]. 
 
First, rolling of leukocytes is mediated by E-selectin and P-selectin of activated ECs. It 
is a low-affinity and reversible interaction with fast on and off rates between the 
selectins and their ligands of leukocytes where the aminoterminal lectin domain of the 
selectins binds carbohydrate groups attaching to the proteins of leukocytes [26]. The 
rolling of the leukocytes allows further activation of the cells by chemokines. The 
chemokine receptors of the leukocytes interact with the chemokines and the integrins 
of leukocyte are activated. The integrin lymphocyte function-associated antigen 1 
(LFA1) of the β2 family binds firmly to ICAM–1 of the immunglobulin superfamily as 
well as the integrin very late antigen 4 (VLA4) of the ß1 family to VCAM–1 [30]. The 
adhered leukocyte reaches by crawling, also called locomotion, the site for 
transmigration with the interaction of integrins and ICAM–1 [31]. Adhesion molecules 
like platelet/endothelial-cell adhesion molecule–1 (PECAM–1) or vascular endothelial 
cadherin (VE-cadherin) lead to transmigration of leukocytes and move to the tunica 
intima [30]. 
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1.1.3 Therapy of atherosclerosis and its pitfalls 
Patients suffering from atherosclerosis can significantly improve the prognosis for CVD 
by changing their lifestyle. These include, for instance, weight loss, termination of 
smoking or physical activity [32, 33]. The second prevention step is the drug therapy 
with β-blockers, statins, angiotensin-converting enzyme (ACE) inhibitors, antiplatelet 
therapy or the new drug proprotein convertase subtilisin/kexin type–9 inhibitor (PCSK–
9) which is intended for patients who are symptom-free or clinically stable [33, 34]. 
Surgery intervention is unavoidable for patients with persistent or exacerbating 
symptoms after the first and second prevention step could not improve the ordeal [35]. 
The discovery of the coronary angiography paved the way for the development of the 
following two surgical techniques: 1) coronary artery bypass surgery (CABG), 2) 
percutaneous transluminal coronary angioplasty (PTCA), recently called percutaneous 
coronary intervention (PCI) due to a broader spectrum. CABG was developed and 
performed in the 1960s by several physicians and Vasilii Kolesov succeeded in a 
sutured anastomosis of a coronary artery to an artery [36]. Afterwards, the performance 
of a saphenous vein-coronary bypass was introduced by Michael DeBakey’s team [37]. 
This surgical revascularization method gained center stage in the treatment of CAD 
and is still of enormous importance, especially for patients with complex lesions [38]. 
In 1977, Andreas Grüntzig achieved another milestone in CAD therapy by laying the 
foundation for PTCA as an alternative treatment [39]. During an angioplasty treatment, 
the stenotic vessel can be expanded via a balloon or stent insertion using a minimally 
invasive catheter inserted (Figure 3). For the implementation of balloon angioplasty, 
various parameters have to be clarified individually for each patient, like the diameter 
of the balloon, the pressure for inflation, and the duration of inflation. Uncoated 
balloons, as well as coated ones are recommended for therapy by the ESC/EACTS 
Guidelines on myocardial revascularization in 2014 [40]. Scheller et al. clearly could 
prove using a paclitaxel-coated balloon which was able to minimize restenosis after 
use of a BMS [41]. Paclitaxel is known as a chemotherapeutic for cancer and is also 
used as an antiproliferative agent in balloons or stents with an antirestenotic effect. 
Drug-coated balloons are different from stent therapy because they do not require 
prolonged dual antiplatelet therapy, leave no foreign body inside the vessel, which can 
lead to restenosis, and release the active substance within seconds. 
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Figure 3: Therapy of atherosclerosis with PTCA and the insertion of a stent. In worst case, it may 
come again after insertion of a stent to narrowing of the vessel lumen, the so-called in-stent restenosis 
(shown in the last vessel). Designed with smart, Servier Medical Art. 
 
Nevertheless, in 2004, a meta-analysis revealed that in non-acute coronary disease 
the insertion of stents reduced mortality rather than balloon angioplasty at 6 months 
[42]. Moreover, the ESC/EACTS Guidelines on myocardial revascularization 
recommend stenting over balloon angioplasty in a first PTCA application [40]. The 
insertion of a stent works via balloon catheter over which the stent is inverted in an 
unexpanded and ‘crimped’ state. Inflation of the balloon causes the stent to expand 
against the arterial wall and remains in that formation as the deflated balloon catheter 
is removed. The first generation of stents belongs to the bare metal stent (BMS). 
However, the risk of an early stent thrombosis and an ISR after stent implantation is 
comparably high [43, 44]. This is due to the occurring trauma to the intimal structure 
as well as an atherosclerotic plaque rupture during stent implantation causing a 
cascade of wound-healing mechanisms, known as neointimal hyperplasia [45, 46]. 
This adverse effect is known as rapid progression of atherosclerosis starting with the 
infiltration of inflammatory cells besides a cascade of various events like smooth 
muscle cell proliferation and migration, platelet aggregation, release of growth factors, 
and extracellular matrix remodeling [45] (described in detail in chapter 1.1.2). The risk 
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of stent thrombosis can be minimized with drugs such as aspirin and platelet 
aggregation inhibitors such as clopidrogel [47], but not the ISR. This unwanted 
occurrence led to the development of the second generation of stents inhibiting 
neointimal hyperplasia: the drug-eluting stent (DES). The DES has as a basic skeleton 
a BMS, which is coated with polymer and drug, and which is delivered to the arterial 
wall after stent implantation. The first two Food and Drug Administration (FDA) 
approved DESs were the sirolimus-eluting Cypher™ stent in 2003 and the paclitaxel-
eluting Taxus™ stent in 2004 [47]. Sirolimus is an immunosuppressive agent and 
paclitaxel an antiproliferative one. These first generation DES agents prevent smooth 
muscle cell proliferation and accumulation of macrophages on the stent, thereby 
reducing the incidence of ISR. Unfortunately, the proliferation of endothelial cells is 
negatively affected as well as the migration, proliferation and differentiation of 
endothelial progenitor cells from blood for the mandatory re-endothelialization of the 
stented region [48]. Further, after discontinuing the dual antiplatelet therapy with 
aspirin and clopidrogel, the risk of late stent thrombosis increases [49]. The 
development of the second-generation DES with thinner struts provoked indeed a 
faster re-endothelialization [50]. However, new approaches for re-endothelialization 
are being sought. One approach for next-generation stents is the coating with anti-
CD34 antibodies to bind the endothelial progenitor cells from the blood to the stent 
[51]. Similarly, the development of bioabsorbable stents is being researched with 
mainly two different materials like polymers, which are degraded by hydrolysis, for 
example poly(lactic acid), and alloys with magnesium [52]. These stents may also be 
provided with an antiproliferative agent to minimize restenosis. Recent results show 
however, that the polymer-based bioabsorbable stents cause more heart attacks than 
the metal stents a few years after insertion. The background probably lies in the 
irregular degradation of the polymers and the deformation of the inserted stent. The 
degradation products of magnesium also appear to have a negative effect [53]. 
Another promising approach is the coating of stents with nucleic acids like siRNA for 
gene silencing, which is described in the following chapters. 
1.1.4 Chances for DES with siRNA against CAMs 
As stated above, the onset of ISR is an inflammatory process that results from injury 
to the intima upon insertion of the stent. A crucial mechanism is the enhanced 
expression of the CAMs like ICAM–1, E-selectin, P-selectin, and VCAM–1 on the 
endothelial cells, which leads to increased binding of leukocytes and platelets with 
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following leukocyte diapedesis into the intima. Additionally, the activation of VSMCs 
induces their proliferation and migration from the media into the neointima producing 
extracellular matrix proteins and a chronic inflammatory process is evoked [28, 54]. 
The focus of research is now on siRNAs directed against these CAMs. Petersen et al. 
proved the effectiveness of an siRNA against VCAM–1 in isloated smooth muscle cells 
(SMCs) from aorta of C57BL/6 mice. The transfected cells reacted in a scratched area 
of an SMC monolayer with reduced migration in comparison to non-transfected cells 
[55]. The inhibition of VCAM–1 by siRNA even reduced restenosis in a surgical 
mechanical de-endothelialized rat carotid [56]. Recently, Sager et al. demonstrated the 
effect of an siRNA mixture of ICAM–1/–2, VCAM–1, E-selectin, and P-selectin on the 
fibrotic cap and necrotic core. The matrix metalloproteinases (MMPs) from 
inflammatory cells are responsible for the degradation of fibrous caps, vessel 
remodeling, and weakening of the atherosclerotic plaques and hence, a further pivotal 
point in the development of DES with siRNA. The mixture of siRNAs provoked 85% 
reduction of mRNA level of several MMPs in mice, protease activity was significantly 
reduced, and plaque collagen was increased leading to smaller necrotic cores and 
thicker fibrous caps [57]. ICAM–1 is of particular interest as it plays a key role in 
leukocyte endothelial adhesion. Walker et al. succeeded in reducing ICAM–1 after 
mimicking an inflammation by TNF-α treatment with siRNA against ICAM–1 [58]. 
Furthermore, Chung et al. demonstrated in a mouse model with flow-induced 
atherosclerosis that polyplexes with siICAM–1 bound to the flow-disturbed endothelium 
and reduced ICAM–1 expression [59]. The idea behind the application of ICAM–1 
siRNA is that early intervention in the inflammatory cascade may inhibit leukocyte-
endothelial adhesion and subsequent processes as SMC mobilization. The other 
participating CAMs, such as VCAM–1 or E-selectin, should also be considered for a 
holistic approach [60]. The advantage of siRNAs used as therapeutic is their specific 
function, which will be explained in the following sections. 
1.2  The RNA interference using small interfering RNA 
RNA interference (RNAi) is a conserved self-defense mechanism in eukaryotic cells 
that prevents the integration of foreign DNA or double-stranded RNA (dsRNA) by 
viruses, transposons or transgenes and regulates gene expression of protein-coding 
genes [61]. In 1990, this mechanism was first revealed in petunia, when it was 
attempted to alter the flower color via the introduction of a gene responsible for flower 
pigmentation [62]. The RNAi mechanism was also described by Fire and Mello, who 
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received the Nobel Prize in Medicine in 2006 for their discovery. They detected the 
mechanism in the nematode Caenorhabditis elegans by introducing dsRNA into the 
organism and the resulting degradation of messenger RNA (mRNA), which is essential 
for the translation of proteins [63]. Understanding the RNAi pathway, it has been 
discovered that the dsRNA was shortened into an RNA piece of approximately 21 
nucleotides (nt), which is called small interfering RNA (siRNA) or micro RNA (miRNA). 
Both small RNAs arise via the RNAi pathway, differing in biogenesis by other proteins 
and complexes. However, the function of repression of mRNA translation is the same 
[64]. In 2001, Elbashir et al. artificially produced 21 nt siRNA for post-transcriptional 
gene silencing in mammalian cell lines, which has paved the way for further promising 
RNAi applications with siRNA [65]. 
1.2.1 The RNAi pathway of siRNA 
The pathway of mRNA degradation by RNAi is divided into two different phases: 1) the 
initiation phase and 2) the effector phase. The pathway is described in Figure 4. In the 
first step, precursor dsRNA from exogenous or endogenous sources enters the 
cytoplasm. There, the long dsRNA is cleaved in a 21–23 nt RNA unit by the 
endonuclease RNase III, called Dicer [66, 67]. The resulting siRNA has a 5’–phosphate 
and a 3’–hydroxyl group with 2–3 nt overhanging 3’–ends on each strand, which are 
necessary for the correct cleavage targeting [68]. With the beginning of the second 
phase, the siRNA is incorporated into the RNA induced silencing complex (RISC) 
containing a sequence-specific nuclease [69]. Here, the ATP-dependent unwinding of 
the siRNA duplex takes place and activates the RISC [70]. Central importance in the 
RNAi pathway is attributed to the Argonaute protein 2 (Ago2) which is located in the 
RISC [71]. Ago2 binds the guide (antisense) strand and extrudes the passenger strand 
[72]. The guide strand of the now single-stranded siRNA guides the endonuclease 
Ago2 to the complementary or nearly complementary target mRNA via base-pairing 
followed by its cleavage [68, 73]. Generally, the mRNA is cleaved in the middle of the 
complementary region, where the siRNA/RISC complex binds [74, 75]. This results in 
an RNA 5’–fragment with a 3’–hydroxyl group and a 3’–fragment with a 5’–phosphate 
group. Due to the unprotected RNA ends, different exonucleases degrade the mRNA 
fragments [76]. The degradation of the mRNA causes the decrease of the mRNA 
amount for translation and consequently, less protein is synthesized and present. The 
RISC can be recovered and can perform multiple cleavage cycles [77, 78]. 
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Figure 4: The mechanism of the RNAi pathway. Designed with smart, Servier Medical Art. The 
illustration is based on basics of the publications [66-75]. 
1.3 Small interfering RNA and its stabilization 
The use of siRNA as a molecular therapeutic agent in acquired and inherited diseases 
is becoming increasingly important. The exogenous, chemically synthesized siRNA 
arises from created algorithms which allows the siRNA to bind to the complementary 
target mRNA. Important parameters for this purpose are for instance: suitable length 
of siRNA, low GC content, and asymmetry between guide and passenger strand with 
a less stable 5’–end of the guide strand [79, 80]. Despite promising therapeutic 
approaches, the main challenging aspects are the stabilization of siRNA, the cellular 
uptake, and its target delivery. Free and naked siRNA runs the risk of being digested 
by endo- and exonucleases that are found in blood, serum, and living cells by 
minimizing its half-live in vivo [81, 82]. Chemical modifications are known to protect 
siRNA from degradation with nucleases by its stabilization. Different modifications at 
the 2’ position of the backbone ribose like 2’-O-methyl, 2’-deoxyribose or 2’-fluoro help 
to stabilize the siRNA at the 3’–end of the guide strand [82-84]. Soutschek et al. was 
able to produce a functional siRNA by chemical modifications of the apoB siRNA, which 
led to a reduction of the mRNA level. The 3’–end of both strands were stabilized using 
phosphorothioate and two 2’-O-methyl nucleotides were added at the 3’ end of the 
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guide strand, while the passenger strand was modified with cholesterol [82]. 
Nevertheless, chemical modifications are often not sufficient for high transfection or 
efficient gene silencing which is partly due to the large molecular weight of about 
13 kDa and the polyanionic character of about 40 negative phosphate charges [85]. 
The way to enable a high transfection rate and the target delivery of siRNA is discussed 
in the following chapters 1.3.1-1.3.3. 
1.3.1 Transfection methods 
For the successful transfection of cells with exogenous RNA, several important 
requirements have to be considered. After the appropriate siRNA has been designed 
and synthesized, the molecular characteristics (as described in 1.1.2) hinder the 
entrance of naked siRNA through the negatively charged and hydrophobic cell 
membrane by passive diffusion. Various methods of transfection are available, such 
as the biological method with viruses as a vector, the physical method by 
electroporation or laser irradiation, and the chemical method with lipids, polymers or 
calcium phosphate [86]. Transfection with genetic material differentiates between a 
stable and a transient one. While in a virus-mediated stable transfection, also called 
transduction, DNA is integrated into the host genome, a transient transfection leads to 
a short-term change in gene expression without integration. Incidentally, in transient 
transfection in vitro and in vivo, the introduced genetic material can be minimized by 
cell division. Due to these facts, the choice of the transfection method depends on 
which purpose would be achieved, for instance up- or downregulation of gene 
expression or the production of recombinant proteins [86]. The chemical transfection 
agents like cationic lipids or cationic polymers are suitable for transient transfection of 
cells and are used in the present thesis for the purpose of substrate-mediated gene 
silencing. 
The chemical transfection agents should fulfill the following aspects for successful and 
efficient siRNA delivery into cells: protection of siRNA against degradation, high 
biocompatibility and low toxicity, uptake into cells, escape from endosomes and 
lysosomes, prevention of errant siRNA compartmentalization (correct localization: 
cytoplasm), siRNA availability at the site of action, and maintaining siRNA gene 
silencing activity [87]. 
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1.3.2 Lipids and liposomes as transfection agent 
Lipids or liposomes are often used for siRNA transfection due to their advantages as 
a reliable delivery vector. Lipids consist of a positively charged, hydrophilic head with 
nitrogen atoms which interacts with the negatively charged sugar-phosphate backbone 
of the nucleic acid. The spacer of the lipid is followed by the hydrophobic tail with 
hydrocarbon chains [88]. The amphiphilic character of lipid molecules enables the self-
assembly of lipid bilayers followed by the formation of liposomes due to energetic 
advantages [88]. Within the liposomes, polar drugs, such as the nucleic acid, can be 
encapsulated in the aqueous core for gene delivery. The lipid structure has the great 
advantage that the head group can be modified and the neutral lipid can be changed 
into a negatively or positively charged lipid. Cationic lipids are produced by modifying 
the head group with positively charged amine groups and are eminently suitable for 
the transfection of the polyanionic nucleic acids including siRNA. The negatively 
charged phosphate backbone of the siRNA interacts via electrostatic binding with the 
positively charged head group and the so called lipoplex is formed by self-assembly 
[89]. The mixing ratio of nucleic acid and lipid is crucial for the subsequent liposomal 
net charge [90]. A slight positive net charge of the lipoplex enables the interaction with 
the negatively charged cell membrane and the following uptake mainly by endocytosis 
[89]. Although the mechanism of lipoplex release from the endosome cannot yet be 
fully explained, Elouahabi and Ruysschaert suggest that a detergent-like 
destabilization of the endosomal membrane releases the lipoplexes into the cytosol 
[90]. After the interaction of the lipoplex with different cell organelles like the 
endoplasmic reticulum, Golgi, mitochondria, and nuclear membrane, the complex 
dissociates and releases the nucleic acid into the cytosol [90]. 
A well-known cationic lipid for siRNA transfection is the commercially available 
Lipofectamine consisting of two different lipid types: 2,3-dioleyloxy-N-
[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate 
(DOSPA) and 1,2-dioleoyl-sn-glycero-3-phosphoetanolamine (DOPE). The cationic 
lipid DOSPA and the neutral lipid DOPE occur in the ratio 3:1 [88]. DOPE is considered 
as a helper lipid because it destabilizes the endosomatic membrane and thus the 
lipoplex ends up in the cytosol [91]. The formation of the lipoplexes with siRNA is very 
simple, since only the two products are mixed together. However, care should be taken 
that the mixing ratio of nucleic acid and lipofectamine matches because uncomplexed 
cationic liposomes may compete with the lipoplexes during transfection process [90]. 
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1.3.3 Polycationic transfection agent 
Cationic polymers can bind nucleic acids via electrostatic interactions and, like cationic 
lipids, are an excellent carrier for transfections. The complexation of cationic polymers 
and nucleic acids is called polyplex. Several polycationic molecules are known as 
potent candidates like the natural polymers chitosan, atelocollagen or the synthetic 
polymers like poly-L-lysine or poly(ethylenimine) (PEI). Among them, PEI is one of the 
most popular synthetic polymers for nucleic acid delivery, as it was discovered as the 
first transfection agent in 1995 [92]. An important chemical property is the high cationic 
charge density. PEI possesses an amino nitrogen on every third atom that can be 
protonated in an endosome [92]. Therefore, PEI is capable to act as a buffer at virtually 
any pH, protects the nucleic acids against lysosomal degradation and provokes the 
influx of chloride anions. Water is thereby drawn into the endosome and osmotic 
swelling is the result. This ‘proton sponge effect’ is responsible for the bursting of the 
endosome and the following release of PEI-nucleic acid complexes into the cytoplasm 
[93]. Successful transfection efficiency is influenced by several characteristics of the 
polymer like the choice of branched or linear polymer structure, the molecular weight 
with the possible occurrence of toxicity as well as the nitrogen/phosphate (N/P) ratio. 
For each transfection, these parameters and the type of cells to be transfected should 
be taken into account. Branched PEIs are known to have greater ability to complex 
nucleic acids compared to the linear ones, since the structure here is more flexible 
(Figure 5). Unfortunately, branched PEIs provoke stronger complexation and smaller 
transfection complexes which leads to lesser transfection efficiency [94]. 
Likewise, the molecular weight is of great importance for transfection efficacy, as the 
molecular weight of PEI increases, the toxicity also increases [95]. The cytotoxic effects 
are probably caused by the permeabilization of the cell membrane [96]. Here, 
Zintchenko et al. described the modification of branched 25 kDa PEI with organic 
substances like ethyl acrylate, succinic or acetic anhydride, and 3–propionic acid which 
caused an improvement in compatibility and a reduction of the toxicity [97]. Another 
possibility is to combine PEI polyplex applications with the natural polymer hyaluronic 
acid (HA), as HA is able to reduce the cytotoxic effects of PEI [98, 99]. The N/P ratio 
has also a crucial meaning for an efficient gene delivery. The ratio is defined as 
quotient of the moles of the positive charged amine groups of the cationic polymer to 
the negative charged phosphate groups of the nucleic acid. The ratio determines the 
size of the particles and as N/P ratio increases, the complex sizes decreases [100-
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102]. A complex size of about 200 nm should not be exceeded [100]. Nevertheless, it 
is imperative to test polyplexes from PEI for the respective cell type, since this can 
react differently to the transfection complexes. 
 
 
Figure 5: Branched and linear PEI. The branched molecule is known to complex nucleic acids more 
easily than the linear one due to its greater flexibility. The figure is adopted from Demeneix and Behr, 
2005 [103]. 
 
1.3.4 Therapeutic potential of RNAi with siRNA 
The possibilities for using siRNA therapy for gene silencing are very diverse and 
currently of particular interest for the development of new therapeutic approaches. Due 
to the RNA interference mechanism, targeted siRNA therapy can be used to switch off 
genes coding for proteins and are associated with a disease. Although RNAi therapy 
is referred to as gene therapy by the regulatory authorities, siRNA is not integrated into 
the genome. The siRNA only intervenes in the process of gene expression for a certain 
time. This has the advantage that the therapy can take place as long as it is necessary 
and desired for the cure of a disease. Great hopes are placed in the siRNA therapy, 
especially in diseases that are not yet to cure or show only moderate success 
according to the state of current therapies. These include the fight against viral 
infections such as HIV or HBV, the treatment of neurological diseases like Parkinson’s 
disease or amyotrophic lateral sclerosis (ALS), the therapy of different cancers, the 
elimination of inflammatory processes [104], such as atherosclerosis and in-stent 
restenosis (ISR). In fact, the world’s first siRNA therapeutic was developed by Alnylam 
and approved by the FDA in August 2018. ONPATTRO™ is a lipid siRNA complex 
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injection and used for the therapy of the polyneuropathy of hereditary transthyretin-
mediated amyloidosis [105]. 
1.4 Delivery systems for siRNA gene silencing 
The way of clinical administration of therapeutic siRNA is important for therapeutic 
success besides the above-mentioned stabilization of the siRNA. Three different 
delivery systems for siRNA are approved in clinical therapy: systemic, targeted, and 
local delivery. Each application has its advantages and disadvantages and should be 
considered when developing an siRNA application system. A systemic delivery system 
is easy to realize in clinical application and is often used in therapeutic cases, where 
the target of interest is quite difficult to reach or is widely found in the body, as in cancer 
or metastases. The administration of the therapeutic agent can occur via intravenous 
or intraperitoneal injections and oral administration, respectively [106-108]. However, 
in this mode of administration, a systemic infiltration of the drug takes place, care being 
taken to ensure that no uninvolved cells or tissues are affected in their function by 
siRNA transfection. Release systems can be developed that bind targeted by specific 
binding to the place where gene silencing is desired to prevent adverse side effects. 
Targeted release of an siRNA silencing therapeutic can ensure the accumulation of 
the therapeutic at the target site, as is often desired in clinical applications. 
Consequently, the amount of drug can be reduced for therapy. An excellent approach 
for targeted siRNA delivery in cancer therapy is the folate-mediated uptake, as cancer 
cells overexpress the folate receptor [109]. Folate can be covalently linked to siRNA 
for instance with poly(ethylene glycol) (PEG) for successful gene silencing [110]. 
Further modification approaches are the linkage of antibodies or antibody fragments 
and the arginine-glycine-aspartate (RGD) sequence [111-113]. Another approach for 
a site-specific siRNA release is the local delivery via local application systems or 
medical devices to different kinds of organs. In this case, unwanted systemic off target 
effects can be avoided and the amount of drugs can be reduced due to the location-
limited release. Several methods have already been successfully tested like the 
intraocular injection of siRNA Bevasiranib (Acuity Pharmaceuticals) as well as 
Ranibizumab (Merck-Sirna therapeutics) for inhibiting neovascularization as a therapy 
in wet-age macular degeneration [114]. Likewise in respiratory diseases caused by 
viral infections, a local intranasal administration with siRNA may be a treatment option. 
Alnylam Pharmaceuticals developed successfully an antiviral siRNA for the treatment 
of the respiratory syncytial virus provoking no side effects [115]. Some experimental 
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approaches also show great promising results such as an siRNA collagen-
chitosan/silicone membrane for reducing scars in wound healing or an siRNA 
poly(caprolactone)-PEG nanofibrous mesh for the treatment of diabetic ulcers [116]. 
Local delivery of siRNA shows great potential in the field of atherosclerosis or 
associated (in-stent) restenosis. The long-time delivery by stents or short delivery by 
balloons might be methods of choice to prevent the progression of inflammatory 
processes. In the next chapter, different approaches to local nucleotide acid release in 
combating atherosclerosis will be discussed. 
1.4.1 Local delivery in atherosclerotic therapy 
Although BMS and DES are well accepted in atherosclerotic therapy, the above 
mentioned pitfalls require new therapeutic strategies in stent or balloon angioplasty 
therapy. Various efforts have already led to promising results in recent years. San Juan 
et al. developed a gene silencing stent coating of cationized pullulan hydrogel which is 
loaded with siRNA targeting MMP2 in VSMCs. The siMMP2 loaded stent was 
implanted in balloon-injured hypercholesterolemic carotid arteries of white rabbits 
leading to a significant reduction of pro-MMP2 and a decrease in MMP2 activity without 
influencing pro-MMP9 [117]. In another study of Li et al., the NOX2 protein (Cybb) was 
down-regulated after balloon angioplasty of carotid artery in an atherosclerotic rat 
model with an amino-acid-based nanoparticle HB-OLD7 and siCybb complex. The 
investigations showed significant reduction of Cybb, NOX2, reactive oxygen species 
production, and neointima formation. Since the NOX2 seems to be the major oxidase 
affecting intimal SMCs, it is a meaningful participant in the development of restenosis 
and atherosclerosis [118]. Focusing on the release system, the polymer PLGA is 
promising for cardiovascular stent coating as a drug carrier as thin coatings or PLGA 
NPs. Currently commercially available DES like Nevo™(Johnson & Johnson) and 
Supralimus™(Sahajanand Medical) with PLGA coating are already being used to 
prevent ISR [119]. A study of Brito et al. demonstrated the effectiveness and long-term 
effect of a PLGA and gelatin coating with eNOS expressing plasmid DNA lipoplexes 
that coated stainless steel stents. The use of stents in a rabbit iliac artery restenosis 
model resulted in eNOS production which provoked suppressed SMC proliferation and 
a re-endothelialization of the artery followed by a significant reduction in restenosis 
[120]. Additionally, Klugherz et al. transfected successfully in pig stent-angioplasty 
studies the arterial wall with plasmid DNA-loaded PLGA NPs that were coated on 
expandable stents [121]. Another promising local delivery system approach is the use 
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of polyelectrolyte multilayers (PEMs) that can be produced using the versatile layer-
by-layer (LbL) technique. The use of positive and negative charged materials creates 
electrostatic interactions that stabilize the structure on the substrate. Several 
biomaterials are popular in PEM research work due to their positive charge like poly(L-
lysine), chitosan, and PEI and their negative charge like alginate, HA, and polyacrylic 
acid [122-127]. PEI is much favored for siRNA PEM build-up, as it forms a non-covalent 
bond with its strong cationic charge density. Because drugs can be incorporated into 
PEMs, this system is predestined for incorporation and a substrate-mediated release 
of siRNA particles for gene silencing [128-134]. Hossfeld et al. established a PEM 
depot system with HA and incorporated fluorescence labeled siRNA/chitosan NPs. Cell 
culture tests with ECs demonstrated the occurrence of siRNA NPs until day six in the 
cells. The coated stent with HA and siRNA/chitosan NPs provoked an uptake of the 
siRNA NPs in the cells of the arterial wall in an ex vivo model with carotid porcine 
arteries [133]. 
1.5 Characteristics of biomaterials for medical applications 
Biomaterials are of natural or synthetic origin and are used for medical devices or 
implants where they come into contact with the biological system. Generally, 
biomaterials are used to support or replace a damaged organ or tissue. It is therefore 
essential that the implanted biomaterial does not induce short-term or long-term 
defense reactions in the body or cause life-shortening damage. Biomaterials can be 
divided into three fields: bio-inert materials that do not interact with the tissue and do 
not trigger an immune response, bioactive materials that can mimic natural tissue, and 
biodegradable materials that are absorbed by the body and replaced by tissue 
regeneration [135]. Bioactive biomaterials are of particular interest for research in 
biomaterial-based devices as the biomaterial can be modified by introducing biological 
agents, drugs, peptides, and nucleic acids or by transforming it via temperature change 
or light and is therefore comparable with a drug. 
When developing a biomaterial for the biotechnology field or medical application, the 
following aspects are of importance: the interaction between the biomaterial surface 
and the cells, the stability or instability of the material with respect to degradation, the 
micro- and macro-mechanical properties compared to the tissue and the ability to 
sterilize the biomaterial [136]. In addition, the proof that the material or the medical 
device is biocompatible is a prerequisite for market approval and is defined in EN ISO 
10993. The product, which may later come into contact with tissue, blood or other body 
Introduction  18 
fluids, is hereby investigated for possible side effects. For this, different tests can be 
carried out in cell culture experiments already during the selection of the biomaterial 
and during various development steps of the medical device. These include for 
instance the determination of the cell adhesion and morphological evaluation, the 
examination of an immune response and cytotoxicity as well as the hemocompatibility. 
1.5.1 Biomaterials for bioactive applications and gene delivery systems 
One of the most popular and FDA-approved biomaterial in drug delivery systems is 
poly(lactic-co-glycolic acid) (PLGA) that is a copolymer of poly lactic acid (PLA) and 
poly glycolic acid (PGA) [137, 138]. A significant advantage of PLGA in medical 
applications is the low systemic toxicity it exerts. The majority suggests that PLGA 
degrades by hydrolysis. However, it cannot be completely ruled out that enzymes are 
involved in the degradation process. During hydrolysis, the ester bond is broken and 
the monomers PLA and PGA are formed. Lactic acid naturally occurs in the 
tricarboxylic acid cycle and therefore PLA can be included in this cycle, metabolized 
and excreted as water and carbon dioxide [138]. Presumably, the same thing happens 
with PGA or it is excreted via the kidneys [138]. For the development of a bioactive 
coating for implants, the duration of the degradation is mostly important, so that the 
duration of effect can be maintained for the respective application. The physico-
chemical properties of PLGA like the molecular weight, the end groups that can be 
capped or uncapped, and PLA:PGA ratio determine the degradation time from months 
up to years [139-141]. A higher content of PGA leads to a faster degradation of PLGA 
with the exception of PLGA 50:50 with the fastest degradation time of one to two 
months [142, 143]. 
A naturally occurring polymer which is often used as a biomaterial in different 
applications is HA. It is a negatively charged glycosaminoglycan consisting of D-
glucuronic acid and N-acetyl-D-glucosamine linked by ß–1,4– and ß–1,3–glycosidic 
bonds [144]. HA is a major component of the extracellular matrix and occurs in 
biological fluids like synovial fluid, umbilical cord and blood with a molecular range from 
103–107 Da [144-147]. Due to its biocompatibility, biodegradability, and no signs of 
immunogenicity, HA is excellent for wound healing, treatment of osteoarthritis, and for 
scaffolds in tissue engineering [148-151]. Although HA is not a classic transfection 
agent because of its negative charge, it is often used in combination with biomaterials 
like chitosan, poly-L-arginine, collagen or PEI for nucleic acid delivery and is able to 
reduce cytotoxic effects of PEI as mentioned before [98, 152-155]. Likewise, HA seems 
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to enhance transfection. An experiment by Han et al. showed that the complex of PEI-
siRNA/HA provoked higher gene knockdown in different tumor cells than the complex 
without HA [98]. HA is also able to interact with cell surface receptors like HA-mediated 
motility receptor, CD44 or ICAM–1 that are responsible for cellular processes like 
migration, proliferation, differentiation and angiogenesis [156-160]. Since CD44 and 
ICAM–1 are over-expressed in atherosclerotic processes, it seems likely that good or 
better transfection results can be achieved in combination with HA. 
Atelocollagen (ATCOL) is an enzymatically modified collagen type I without 
telopeptides, the N- and C-terminal ends [161]. The modification leads to the absence 
of immune stimulatory effects and the biocompatibility of collagen creates a well-
tolerated material for medical application like cartilage repair or wound-healing [162, 
163]. ATCOL can exist in different states of aggregation depending on the temperature 
and concentration. ATCOL is liquid when temperature is below 10° C and a gel at 37° C 
with a concentration above 0.5%. Higher concentrations cause liquefaction of the 
polymer with a viscosity similar to blood. Several studies dealing with the delivery of 
siRNA confirmed ATCOL as a potent carrier as well as an amplifier for gene silencing 
and protector against nucleases [162, 164-167]. Takei et al. demonstrated the gene 
delivery efficiency of ATCOL with siRNA against VEGF [168]. The polyplex remained 
for at least 8 days in the tumor tissue, whereas naked siRNA showed low persistence 
at day 1, and no occurrence at day 8. Furthermore, the tumor growth and the 
microvessel density were lower than in the control showing the efficiency of 
siRNA/ATCOL transfection. 
Introduction  20 
1.6 Aim of the thesis 
Cardiovascular atherosclerosis is often treated by PTCA, in which a stent can be 
inserted at the affected narrowed site. Unfortunately, inserting a BMS or a DES may 
damage the endothelium, causing a wound-healing mechanism, followed by an ISR or 
stent thrombosis. The mechanism causes an up-regulation of the CAMs like ICAM–1, 
VCAM–1, E-selectin and P-selectin. Thus, the leukocytes have more receptors 
available, to which they can bind and migrate into the tunica intima – a chronic, 
inflammatory process arises. The pivotal point of the thesis was the establishment of 
bioactive surface coatings consisting of a biomaterial and an embedded, complexed 
siRNA against the endothelial surface receptor ICAM–1 for local gene silencing. This 
approach is intended to further develop eluting stents with the aim of specifically 
minimizing the expression of ICAM–1 to prevent ISR. For this purpose, different 
biomaterials, such as natural or synthetic polymers should be applied to model 
substrates. Monolayer and multilayer systems, as well as polyelectrolyte layers should 
be investigated for the release of complexed siRNA particles. The biocompatibility of 
the polymers could be determined either with fluorescence microscopy, cell viability or 
cell number. Different siRNA complexes should be evaluated with a liposomal 
transfection reagent and a cationic synthetic polymer as transfection reagent. One 
intention was the substrate-mediated transfection of an endothelial cell line with the 
embedded and complexed siRNA particles. Therefore, the transfection efficiency of 
these siRNA particles should be determined by flow cytometry. Also, a major aim of 
this thesis was the substrate-mediated gene knockdown of ICAM–1. The ICAM–1 
expression of the receptors should be examined by flow cytometry after TNF-α 
activation and antibody staining. Additionally, the site specific ICAM–1 knockdown by 
siICAM–1 can be proven by 5’-RLM-RACE-PCR. Of particular interest in terms of stent 
or balloon coatings are the duration of the siRNA release from the coatings, the 
duration of transfection and gene knockdown. The supernatants and the coated 
substrates of the incubated biomaterials with fluorescence labeled siRNA should be 
examined for their fluorescence intensity with a fluorescence reader. Since the long-
term goal of this work is clinical application, the hemocompatibility of the coatings 
should be confirmed as well as a possible immune response against the biomaterial 
and siRNA lipoplexes. 
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2 Results 
2.1 Publication I 
Koenig O., Nothdurft D., Perle N., Neumann B., Behring A., Degenkolbe I., Walker T., 
Schlensak C., Wendel HP., and Nolte A. 
An atelocollagen coating for efficient local gene silencing by using small interfering 
RNA 
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CVDs lead the mortality statistic on a global scale with 17.3 million deaths per year and 
caused especially with CHD 20% dead in the European population. The development 
of a CHD is mainly triggered by atherosclerotic processes. Different treatment 
strategies like medication with ACE inhibitors, antiplatelets, and ß-blockers or surgical 
interventions by CABG or PTCA with or without stent insertion are helpful and widely 
used. Nonetheless, tissue trauma in the tunica intima often occurs after deployment of 
stents, resulting in ISR. The trauma creates an inflammatory process that causes the 
endothelial cells to increasingly express adhesion molecules such as E-selectin, 
VCAM–1 and ICAM–1. Leukocytes migrate via leukocyte diapedesis into the tunica 
intima and cause proliferation of smooth muscle cells and further inflammatory 
processes. Re-narrowing and an occlusion of stented atherosclerotic vessel is the 
result. DESs release anti-proliferative agents to counteract neointimal hyperplasia. 
However, these agents are suspected to cause unwanted late restenosis as they 
prevent re-endothelialization of the vessel. The aim of this study was to develop a local 
siRNA delivery system as a stent coating for the endothelial adhesion molecule ICAM–
1 which is able for long-term release and ICAM–1 knockdown. ATCOL, known for its 
low immunogenicity, was selected as a suitable biomaterial with transfection and depot 
effect. First, the most biocompatible ATCOL coating was determined by testing four 
different ATCOL concentrations on cell viability with EA.hy926 cells. ATCOL coatings 
of 0.008%, 0.016%, 0.032%, and 0.064% solution were prepared by diluting the stock 
solution with 5 mM sodium acetate buffer (pH 5.5) and 100 µL were air-dried on glass 
slides (10 x 10 x 1 mm). The cell viability was tested after 48 h cultivation of EA.hy926 
seeded onto the coated glass slides by determination of the cell number by CASY cell 
counter and by microscopy images. The coatings of 0.008%, 0.016%, and 0.032% 
showed instead of 0.064% no significant decrease in cell number and morphology and 
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were comparable to the cells cultured on the uncoated glass control. Therefore, in the 
following experiments, the 0.008% and 0.032% ATCOL coatings were tested as 
possible siRNA transfection coatings. Both ATCOL solutions were mixed with different 
siRNA-Lipofectamine®2000 solutions of 1 µg siRNA + 1 µL Lipofectamine, 2.5 µg 
siRNA + 2 µL Lipofectamine, and 5 µg siRNA + 3 µL Lipofectamine and incubated for 
20 min for complexation before 100 µL were air-dried on glass slides. ATCOL/siRNA 
coatings were observed for the release kinetic of siRNA AF 488 particles and the 
transfection efficiency with and without Lipofectamine by flow cytometry. The ICAM–1 
expression was tested with ATCOL/siICAM–1 coatings after 48 h cultivation of 
EA.hy926 on coated glass slides and activation with TNF-α for 14 h. Long-term 
knockdown of ICAM–1 was determined over eight days with cells either cultivated on 
ATCOL/siICAM–1 coated glass slides or cells seeded one day prior experiment before 
incubation with ATCOL/siICAM–1 complexes in liquid form for 4 h and replaced by cell 
culture medium. The siICAM–1 mediated cleavage site of ICAM–1 mRNA after 
transfection was analyzed with the 5’-RLM-RACE-PCR technique. Hemocompatibility 
of the coatings was determined with human blood incubation and ELISAs. The 
transfection potential of ATCOL was tested using the transfection efficiency and ICAM–
1 knockdown experiments. No significant transfection efficiency could be detected with 
0.008% or 0.032% ATCOL/siRNA AF 488 coatings without the use of Lipofectamine. 
The addition of Lipofectamine resulted in a significant increase in efficiency with a 
maximum value of 68.9% positive cells with 5 μg siRNA and 0.008% ATCOL coating, 
and 75.2% with the same amount of siRNA and 0.032% ATCOL. The ICAM–1 
expression of cells cultivated on 0.008% ATCOL and siICAM–1 without Lipofectamine 
also showed no reduction of the ICAM–1 expression. However, coatings with 
Lipofectamine caused a concentration dependent decrease in expression. An ICAM–
1 knockdown of 47.9% was observed with 0.008% ATCOL and 5 µg siRNA showing 
significant decrease compared to the control with siSCR (scrambled siRNA). The same 
results were achieved with the 0.032% coating, whereby a higher ICAM–1 knockdown 
of 60.4% was seen here. The long-term knockdown experiment revealed the 
effectiveness of the ATCOL-mediated local transfection in comparison to the 
conventional transfection, where transfection particles linger in suspension. The 
0.008% ATCOL and 5 µg siICAM–1 coating achieved significant knockdowns after 
cultivation day 2, 4, and 6 and a knockdown until day 8 with 11.6%. Highest knockdown 
was seen on day 2 with 68.9%, followed by day 4 and 6 with 63.3% and 48.7%, 
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respectively. In contrast, transfection particles in suspension could not provoke a 
significant ICAM–1 knockdown during the whole experiment and furthermore, showed 
significant higher ICAM–1 values until day 6 in comparison to the ATCOL/siICAM–1 
coatings. The 0.032% coating caused a lower knockdown than the 0.008% ATCOL 
coating, and therefore, only a significant reduction of ICAM–1 expression was seen 
until day 4. Additionally, there were no significant ICAM–1 differences between the 
ATCOL coating- and the suspension-mediated transfection process. Knockdown with 
41.1% and 41.0% was observed on day 2 and 4. The results of the release study were 
comparable and in line with the knockdown experiments. After 9 days release of siRNA 
AF 488, 0.032% ATCOL with 5 µg siRNA contained the highest residual amount of 
siRNA followed by 0.008% ATCOL with the same amount siRNA. A significant 
difference between 1 µg and 5 µg siRNA AF 488 with 0.032% ATCOL coating was 
observed at this time. The highest amount of siRNA release from all coatings happened 
within the first 4 h. After 24 h, the release rate of 0.008% ATCOL coating was higher 
than the one of the 0.032% coating. The specific mRNA degradation by knockdown 
experiments with ATCOL/siICAM–1 coatings was proven with the 5’-RLM-RACE-PCR 
technique. The specific cleavage site at bp 1,818 was detected only with this coating 
and not in control layers without siICAM–1. The hemocompatibility of the highest 
concentration 0.032% ATCOL/siICAM–1 coating was analyzed after 1 h incubation 
with human blood. The cell numbers of leukocytes, erythrocytes, platelets, 
lymphocytes, monocytes and granulocytes showed no significant changes in 
comparison to the 1 h control. Additionally, SC5b9 and C3a of the complement system 
and PMN elastase also revealed no change in values. Furthermore, a significant 
increase in hemolysis values was detected, wherein the limit for hemolysis of 
40 mg/100 mL was not exceeded. 
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2.2 Publication II 
Koenig O., Zengerle D., Perle N., Hossfeld S., Neumann B., Behring A., Avci-Adali M., 
Walker T., Schlensak C., Wendel HP., and Nolte A. 
RNA-eluting surfaces for the modulation of gene expression as a novel stent concept 
 
Pharmaceuticals, 2017 February; 10(1): 23 
 
The coronary artery disease is caused by atherosclerosis in heart coronary vessels 
triggering stroke and heart attack. A common treatment used in vasoconstriction is the 
established PTCA method. In this minimally invasive procedure a balloon catheter can 
be introduced, with which at the same time a coronary stent can be placed at the 
affected atherosclerotic site. Nevertheless, the insertion of stents, such as BMS or DES 
involves the risk of ISR or stent thrombosis. Placing of the metal mesh at the affected 
artery damages the endothelial cells in the tunica intima and provoke atherosclerotic 
plaque rupture. Consequently, the wound-healing mechanism, called neointimal 
hyperplasia, starts with the first step: inflammatory cell infiltration. Inflammatory 
mediators and chemoattractant factors recruit leukocytes from the blood system for 
their diapedesis at the damaged tissue. ECs react with an enhanced expression of 
their binding sites, the CAMs like ICAM–1, VCAM–1, E-selectin, and P-selectin. The 
leukocytes adhere on the endothelial binding sites and migrate into the tunica intima. 
Additionally, the vascular smooth muscle cells proliferate and migrate from the intima 
to the neointima due to the chronic inflammatory process. A promising approach to 
circumvent these adverse effects by bare metal stents was the development of DES 
with chemotherapy medication or immunosuppressants. Although ISR could be 
reduced up to 60%–80%, DESs provoke slow re-endothelialization causing a late in-
stent thrombosis and demand a prolonged antiplatelet therapy. All these adverse 
effects have to be eliminated with new approaches in the design of drug eluting stents. 
The purpose of this study was to establish a long-term drug-eluting coating system with 
three different derivatives of the approved biomaterial PLGA which were: PLGA 
Resomer® RG 752 H, 75:25, acid terminated, 4,000–15,000 Da (= PLGA 1); PLGA 
85:15, ester terminated, 50,000–75,000 DA (= PLGA 2); PLGA Resomer® RG 756 S, 
75:25, ester terminated, 76,000–115,000 Da (= PLGA 3). The degradation of PLGAs 
by hydrolysis depends on their molecular weight, end groups (capped or uncapped) 
and the PLA:PGA ratio, whereby the increase of PGA accelerates the degradation. 
The eluting drug was siRNA against ICAM–1 alone or with eGFPmRNA together. They 
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were Lipofectamine® 2000–encapsulated and locally transfected. The PLGA was 
freshly dissolved in ethyl acetate before each use with a concentration of 1 µg/µL. 
Coverslips (15 mm diameter) were used for pH value analysis, cell viability assay and 
hemocompatibility test with air-dried coating of 50 µg of each PLGA (1 to 3). For co-
transfection with siRNA and mRNA 13 mm diameter coverslips were air-dried with 
PLGA 1 (50 µg/ µL) containing a transfection mix of 10 µg eGFPmRNA, 3 µg siRNA, 
and 2 µL Lipofectamine. Glass slides (10 x 10 x 1 mm) were coated for all other 
transfection experiments to evaluate transfection efficiency, knockdown and 5’-RLM-
RACE-PCR. For this, Lipofectamine and siRNA were complexed in Dulbecco’s 
Modified Eagle Medium (DMEM) for 30 min with different amounts: 1 µg siRNA and 
1 µL Lipofectamine, 3 µg and 2 µL, and 6 µg and 4 µL. Subsequently, PLGA and 
Lipofectamine/ siRNA complexes were mixed 1:1 and 100 µL of this solution were 
pipetted onto one glass slide. First of all, the degradation of PLGA 1–3 alone was 
tested over four weeks in cell culture medium under standard culture conditions 
regarding the pH value stability. Furthermore, the cell viability of EA.hy926 was tested 
with the supernatants after one, two, three, and four weeks of cultivation of the pH 
value test with the CASY® cell counter and the MTT-assay after 48 h cultivation. 
Hemocompatibility of PLGA 1–3 was tested with fresh human blood after 1 h gently 
shaking at 37° C. Different inflammatory markers were determined after the incubation 
of human vascular endothelial cells (hVECs) with PLGA 1–3 coatings and in 
combinations with Lipofectamine alone or with siICAM–1 or scrRNA by quantitative 
Real-Time PCR (qRT-PCR). The uptake of PLGA-eluting siRNA AF 488 was analyzed 
by flow cytometry after 24 h incubation of coated slides laying on EA.hy926 cells. The 
ICAM–1 knockdown and the ICAM–1 expression was determined after 48 h of 
transfection with coatings consisting of PLGA1–3 and 3 µg siICAM–1/Lipofectamine 
complex by flow cytometry and qRT-PCR with EA.hy926 and hVECs. The ICAM–1 
specific cleavage site was determined with the 5’-RLM-RACE-PCR. PLGA mediated 
long-term release was tested with siRNA AF 488 and a multilayered coating system 
consisting of eight alternately dried layers of 500 µg PLGA and 3 µg siRNA complexed 
with Lipofectamine and a capping layer of 1 mg PLGA. The co-transfection of 
eGFPmRNA and siRNA AF 555 in PLGA 1 was examined by flow cytometry. The first 
result of pH stability examination showed the same variations in pH value in all three 
PLGA samples and the uncoated coverslip control. Lower pH values were observed 
for PLGA 1 after two, three and four weeks and for PLGA 2 after two and four weeks 
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in comparison to PLGA 3. The cultivation of EA.hy926 and the supernatants of PLGA 
1–3 caused no significant changes in cell viability. The highest but not significant 
decrease in cell viability was seen with the three-week-old supernatant, with viability 
decreasing to 85% with the PLGA 2 and 3 supernatant and to 90% with PLGA 1. The 
hemocompatibility of PLGA 1–3 could be proven by the tests with fresh human blood 
after 1 h incubation. The blood cells like erythrocytes, platelets, leukocytes, 
lymphocytes, monocytes, and granulocytes showed no significant changes after 1 h 
incubation with PLGA 1–3 coated slides in comparison to the control slides. Also, no 
significant changes in the values of the parameters of the complement system C3a 
and SC5b9 were found between 1 h control and samples. Significant increases in 
complement system samples and blood parameters were only seen between 0 h 
controls and the 1 h control. The PLGA 1–3 coatings did not provoke a significant 
change within these parameters. The results of ß-Thromboglobulin, 
polymorphonuclear granulocyte (PMN)-elastase, and thrombin-antithrombin III-
complex (TAT) examination with PLGA 1–3 coatings did not differ significantly from the 
1 h control. The analysis of the immune response regarding inflammatory markers 
CXCL–7, CXCL–10, signal transducer and activator of transcription 1 (STAT1), and 
OAS detected no augmentation in mRNA level when only PLGA 1–3 was used. The 
addition of Lipofectamine caused an increase in mRNA expression, which was 
intensified by siICAM–1 and scrRNA. However, dsRNA augmented the mRNA 
expression of CXCL–10, STAT1, and 2'-5'-oligoadenylate synthetase (OAS) to a much 
greater extent. When analyzing the data of the short-term uptake of siRNA AF 488, the 
appropriate amount of siRNA could be determined for further experiments. The amount 
of 3 µg siRNA with Lipofectamine and PLGA 1–3 effected significant higher 
transfection efficiencies than with 1 µg. Although, the increase to 6 µg resulted in the 
highest level with 96% and 95% for PLGA 2 and PLGA 1, this increase was not 
significant. Consequently, 3 µg siRNA was used in the following experiments, whereby 
PLGA 1 revealed the highest efficiency. Also in the knockdown experiment, the 3 µg 
siRNA amount resulted in the highest significant ICAM–1 knockdown of 36% with 
EA.hy926 and the highest knockdown of 22% with hVECs. While significant ICAM–1 
knockdown could be observed with EA.hy926 in comparison to the controls with TNF-
α, PLGA 1 and TNF-α, and PLGA 1 with scrRNA and TNF-α, hVECs did not show such 
clear results. Subsequently, it was demonstrated that the siICAM–1 transfection and 
the following mediated knockdown correctly cleaved the mRNA transcript at the base 
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pair 1818. The long-term uptake experiment of siRNA AF 488 revealed high 
transfection efficiency values until day six and long-lasting efficiency until day twenty. 
Very high values were reached with at least 80% after the first incubation day and 85% 
after the second. PLGA 1 noted the highest efficiency with 96%. Within the third to 
sixth day, efficiency dropped to a baseline of 1–2%. The co-transfection experiment of 
siRNA AF 555 and eGFPmRNA proved that PLGA 1 is suitable as a coating system 
for this purpose. The co-transfection yielded 11% positive cells for siRNA AF 555 and 
eGFPmRNA. Separate transfection of PLGA 1 with siRNA AF 555 complexes showed 
26% positive cells and PLGA 1 with eGFPmRNA 11%. 
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2.3 Publication III 
Koenig O., Neumann B., Schlensak C., Wendel HP., and Nolte A. 
Hyaluronic acid/poly(ethylenimine) polyelectrolyte multilayer coatings for siRNA-
mediated local gene silencing 
 
PLOS ONE, 2019 March; 14(3): e0212584 
 
The RNAi mechanism is a promising approach for various therapeutic applications, like 
infectious diseases, cancer or CVDs with the aim of transient specific gene silencing. 
Local gene silencing is of particular importance for therapeutic approaches where a 
local and specific knockdown via siRNA is desired. PEMs offer the possibility to build 
a construction via the versatile LbL technique into which active agents can be 
integrated and afterwards released. The build-up of PEMs is generally carried out with 
familiar biomaterials of opposite charges such as with the synthetic cationic polymer 
PEI. It is known as a transfection agent for gene delivery with its condensing ability and 
is often used with siRNA. The negatively charged polymer is the naturally occurring 
HA. Its high molecular weight variant is attributed a cytotoxic-reducing effect of PEI.  
During an inflammatory process such as in atherogenesis, different CAMs like E-
selectin, VCAM–1, and ICAM–1 are increasingly synthesized by overexpressed genes 
on activated endothelial cells. The consequence of this is that leukocytes interact with 
the receptors of the CAMs and the diapedesis with previous rolling and tethering 
occurs. In case of stent insertion, the endothelium may be injured at the site of 
placement, which also causes an inflammatory process with leukocyte diapedesis. As 
a result, this can lead to reocclusion of the artery as well as to stent occlusion. Hence, 
in this study an LbL build-up of HA and PEI-siRNA were established and tested as a 
novel local gene silencing construction for the cell adhesion molecule ICAM–1. Herein, 
20 µM siRNA and 25 kDa branched PEI were both diluted in 0.15 M NaCl for 10 min 
and afterwards mixed with a ratio of 18,75 mN/P. After 20 min of incubation, the PEI-
siRNA complexes were ready for LbL build-up on 10 x 10 x 1 mm glass slides. Sodium 
hyaluronate 95% was dissolved with 1 mg/mL in 5 mM sodium acetate buffer (pH 5.5). 
First, precursor layers, consisting of a monolayer with 750 kDa PEI and two following 
bilayers of HA and 25 kDa PEI, were deposited on the slides by a 10 min dipping and 
in between 3 x 2 min washing steps. Bioactive bilayers of HA/PEI-siRNA were applied 
afterwards in the same way.  
Results  29 
Preseeded EA.hy926 cells were incubated in a “reverse assay” for 24 h with the LbL 
coated glass slides. Afterwards, the ICAM–1 receptor expression was examined by 
flow cytometry. Here, control cells incubated with uncoated slides, cells with PEI-
siICAM–1 coated slides, and cells with PEI-siSCR coated slides were stimulated with 
TNF-α for 14 h to induce ICAM–1 expression. However, neither the 3 nor the 10 
bilayers of PEI(HA/PEI)2(HA/PEI-siICAM–1) provoked a significant reduction of the 
ICAM–1 expression. Consequently, the LbL technique was modified by exchange the 
dipping steps of HA and PEI-siRNA to drying steps. An advantage of this technique 
was that the amount of incorporated siRNA could be provided. With every drying step 
of PEI-siRNA, 0.5 µg siRNA was deposited in one bilayer. In this case, the ICAM–1 
expression of EA.hy926 was significantly decreased with PEI(HA/PEI)2(HA/PEI-
siICAM–1)3,5,7,10,12 in comparison to the TNF-α control and to their 
PEI(HA/PEI)2(HA/PEI-siSCR)3,5,7,10,12 controls. The highest ICAM–1 reduction was 
determined with 10 bilayers and 44% remaining ICAM–1 expression.  
Afterwards, this successful established transfection system was tested for transfection 
efficiency with fluorescence labeled siRNA (siRNAf), for duration of siRNAf release and 
ICAM–1 knockdown, and for cell number determination. The transfection efficiency test 
of 3 and 10 bilayers confirmed the effectiveness of the bilayer system with a result of 
50% transfection efficiency using coated slides with PEI(HA/PEI)2(HA/PEI-siRNAf)10. 
Since it was noted in the ICAM–1 knockdown experiment that 12 bilayers could not 
provoke a higher knockdown than 10 bilayers, it was of interest whether a significant 
increase in bilayers can further reduce the ICAM–1 expression. However, the 
augmentation of bilayers up to 24 did not reduce the ICAM–1 expression more than 
the 10 bilayers. To determine the duration of the release, the PEM coated slides 
already cultured for 24 h were cultured again on preseeded cells for further 24 hours. 
A non-significant reduction of ICAM–1 expression was found in both PEMs 
PEI(HA/PEI)2(HA/PEI-siICAM–1)12,24. The release study confirmed this result showing 
an initial burst release within the first hour of all PEM bilayers followed by a minor 
release until 48 h at 37 °C in PBS. Additionally, the fluorescence intensity of the 
completely scanned coated PEMs showed highest values at time point zero before 
incubation and a significant decrease of intensity after 1 h incubation under same 
conditions. The living cell number of PEM PEI(HA/PEI)2(HA/PEI-siICAM–1 or -
siSCR)10 dried coatings was compared to a monolayer with the same amount of siRNA. 
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The results showed a significant reduction of living cell number in the monolayer 
consisting of 5 µg siICAM–1 or siSCR. 
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3 Discussion 
3.1 Efficient local gene silencing mediated by ATCOL coatings with embedded 
siRNA lipoplexes 
Cardiovascular stent therapy needs new ways to improve the outcome of long-term 
therapy. During angioplasty therapy, inserting the stent is seen as a trauma to the 
intimal structure of the arterial wall, resulting in an immune reaction and ultimately a 
re-narrowing of the vessel due to wound-healing mechanisms [169]. The commonly-
used DESs were introduced to inhibit neointimal hyperplasia and consequently, reduce 
the risk of ISR. However, first and possibly also second generation of DESs fail to 
prevent late stent thrombosis after discontinuing the dual anti-platelet therapy [48]. The 
development of gene-eluting stents is a promising new approach for the alteration in 
gene expression involved in vascular wall regeneration. For this purpose, a surface 
coating with ATCOL was developed in this project, which can release a complexed 
siRNA over a longer period of time. Different ATCOL concentrations were tested in a 
cell culture assay with the immortalized EC line EA.hy926 to determine the cell viability 
on the surfaces. ATCOL has the property that its physical state changes depending on 
the temperature and concentration. At a temperature less than 10° C ATCOL is liquid 
and with increasing temperature the protein becomes a gel between room temperature 
and 37° C depending on the concentration [166]. Cultivation of cells on the coatings 
with 0.008%, 0.016%, and 0.032% ATCOL showed cell counts comparable with cells 
growing on the uncoated glass slide. The 0.064% ATCOL coating provoked a 
significant reduction of the cell number in comparison to all samples. In addition, the 
light microscopic images showed an atypical morphology with a rounded cell body and 
hardly any pseudopodia. The stiffness of the substrate plays a crucial role in cell 
adhesion, migration, proliferation, and differentiation [170-175]. Each cell type is 
adapted to its environment and therefore prefers either a hard or a soft substrate for 
cell growth. Also, Nolte et al. achieved lower cell viability and/or adhesion in a softer 
substrate with PEMs from natural polymers compared to a stiffer material with synthetic 
polymers [176]. Likewise, the softer substrate caused the rounding of the cells. 
Consequently, an increasing ATCOL concentration is responsible for softer coatings. 
During the development of a gene-releasing coating, release and transfection are the 
pivotal point. Despite literature statements from studies with ATCOL [161, 162, 165, 
166], the embedded siRNA particles did not allow efficient uptake into the cells with 
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0.008% and 0.032% ATCOL concentrations in combination with 1, 2.5, and 5 µg siRNA 
AF 488 after 48 h. Likewise, no reduction of the ICAM–1 protein could be achieved 
with these coatings when using siRNA against ICAM–1. Other studies, however, 
showed successful transfection with an efficiency of 40–60% with 0.008% ATCOL 
layers and gene silencing with siRNA [161, 177]. The difference with our static method 
is that the coating was made by rotating the ATCOL solution with siRNA. This could 
be the reason for the different efficiencies and outcome as well as the use of other cell 
lines. By complexing the siRNA with Lipofectamine®2000, the transfection efficiency 
could be significantly increased. Highest transfection efficiency was reached with 5 µg 
fluorescent-labelled siRNA and 0.008% ATCOL with 68.9% fluorescence positive cells 
and 0.032% ATCOL with 75.2%. Overall, the 0.032% ATCOL coatings provoked higher 
transfection efficiency values than the 0.008% ATCOL. 
The gene silencing of ICAM–1 was tested in a short-term experiment with 0.008% and 
0.032% ATCOL coatings with embedded 1, 2.5 or 5 µg siICAM–1 lipoplexes. A 
significant reduction in ICAM–1 was achieved with 5 µg siICAM–1 and the 0.008% and 
0.032% coatings, respectively. Thus, the ICAM–1 gene silencing approach for 
preventing the leukocyte adhesion cascade could be a promising therapeutic option to 
prevent an inflammatory process after stent placement. This involves intervening in an 
early state of wound healing before the inflammatory process provokes for instance 
the SMCs recruitment [28, 54]. The functionality of the local ATCOL delivery system 
with embedded siICAM–1 lipoplexes showed the proof of the correct cleavage site for 
the ICAM–1 mRNA by 5`-RLM RACE PCR by 5-RLM RACE. This demonstrates that 
the gene silencing of ICAM–1 was due to the specific siRNA for ICAM–1 and no side 
effects have influenced the process. 
Since sustained release of the lipoplexes is desired for substrate-mediated gene 
silencing, release with complexed siRNA AF 488 to day 9 was tested. The combination 
of 0.032% ATCOL and 5 µg siRNA showed the highest release over time until day 9 
followed by 0.008% ATCOL and 5 µg siRNA. An initial burst release within the first 4 h 
was observed followed by a sustained release until the end of the experiment. In the 
first days of transfection, burst release seems to be an important prerequisite for high 
and long lasting gene silencing [178, 179]. The difference between the releases of the 
siRNA AF 488 with the two differently concentrated ATCOL coatings is due to the 
collagen matrix density. A lower collagen concentration leads to a reduced matrix 
density, which leads to a faster escape out of the matrix [167]. The results of the 
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release study and of the long-term transfection experiment support this finding of Sano 
et al. 
During the long-term gene-silencing experiment, the superiority of substrate-mediated 
transfection and gene silencing compared to the suspension-mediated variant was 
clearly demonstrated with 0.008% ATCOL coating and 5 µg siICAM–1. The gene 
silencing of ICAM–1 was significantly higher until day 6 using substrate-mediated 
transfection and the gene silencing still showed a knockdown of 11.6% on day 8, 
whereas no effect was seen in the suspension-mediated transfection. In general, the 
0.032% ATCOL coating could not provoke such considerable ICAM–1 knockdown 
values and significant gene silencing was observed until day 4 by substrate-mediated 
transfection. The higher transfection efficiencies and higher release values of 0.032% 
ATCOL with 5 µg siRNA could be explained by chemical processes. If the amount of 
ATCOL for the complexation of the siRNA is increased next to Lipofectamine, the two 
positively charged substances compete for the negative siRNA. Therefore, there could 
be more naked siRNA, which increases levels in the release and transfection efficiency 
study. Consequently, naked siRNA could be degraded by nucleases and led to lower 
gene silencing with 0.032% ATCOL coating. 
With regard to application of the coating on coronary stents, the hemocompatibility of 
ATCOL/lipoplex coating was proved. No significant reduction of blood parameters was 
observed and the parameters of the complement system SC5b9 and C3a as well as 
the PMN elastase were not increased. Additionally, the coatings provoked no 
hemolysis. 
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3.2 PLGA layers for the modulation of ICAM–1 gene expression as a stent 
concept for atherosclerosis 
As already mentioned, new approaches to PTCA treatment with the insertion of stents 
are being sought in order to improve the outcome. The combination of gene therapy 
and eluting stents may be important for the suppression of the inflammatory reaction 
after stent insertion. Gene therapy is a promising approach because it can be used to 
target and control the expression of proteins [180]. The aim of this study was to develop 
and evaluate a long-term release coating for siRNA delivery with the FDA- and EMA-
approved biomaterial PLGA for the healing of the artery which can take up to three 
months [181]. The three PLGA 1–3 resomers with different lactide:glycolide ratios, 
different molecular weights, and end-capped or non-end-capped polymers proved their 
biocompatibility by one aspect, which was checking the pH value of the cell culture 
medium with PLGA coated slides and the cell viability after cultivation with EA.hy926. 
During the hydrolysis of PLGA, acids are formed which are considered to be a 
disadvantage for the use of the biomaterial in drug release [182]. However, the pH 
value showed no shift in the acidic region, but remained in the neutral to basic range. 
Presumably, the cell culture medium with its buffering properties is responsible for the 
stability of the pH and the slight basic shift is due to the storage in the refrigerator. 
PLGA 1 coatings showed a lower pH value from the second to the fourth week 
compared to the other PLGAs. This confirms the fact that PLGA 1 degrades faster with 
its smaller molecular weight and free carboxyl end groups than PLGA 2 and 3 with 
capped end groups [140, 141]. All three PLGA coatings were considered non-toxic as 
cell viability remained constant during the first and second week and decreased less 
than 30% in the third and fourth week (according to EN ISO 10993–5). In addition to 
non-cytotoxic effects, hemocompatibility as another aspect for biocompatibility also 
plays an important role in the development of a bioactive coating. This includes, for 
example, that the coating does not affect blood parameters, the complement system 
is not activated, and the platelets are not activated and aggregated. The 
hemocompatibility of the three PLGA coatings has been proven by not detecting any 
decrease in the number of platelets, leukocytes, lymphocytes, monocytes, and 
granulocytes. This suggests that there is no unwanted adhesion of blood cells to the 
polymer coating. Furthermore, activation of the complement system and the platelets 
can be ruled out since the associated parameters such as ß-Thromboglobulin, TAT, 
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PMN-elastase, C3a, and SC5b9 showed no change after blood incubation. 
Consequently, there is no risk of thrombus formation due to the PLGA coating. 
Since in one of our previous study, the activation of inflammatory markers was detected 
by Lipofectamine, this effect was also observed here [183]. While the PLGA did not 
increase the expression of the inflammatory and interferon response markers, the 
addition of the Lipofectamine resulted in an increase in the markers. In addition to the 
specific binding of the siRNA, a binding to the Toll-like receptor 3 may also occur, as 
in the case of the dsRNA, where a very high reaction takes place. 
The main focus of the study was on the determination of transfection efficiency and 
gene silencing of ICAM–1 via PLGA-mediated delivery. The preliminary short-term 
study showed that even with 3 μg siRNA AF 488 and PLGA 1 the highest transfection 
efficiency (95%) with fluorescent labelled siRNA was achieved. PLGA 2 and 3 showed 
significantly lower efficiency values. Although an increased siRNA amount of 6 μg 
increased the efficiency in the coating with PLGA 2 and 3, the values were not 
significantly different from 3 μg siRNA. This means that the cells are already saturated 
with an amount of 3 μg siRNA and increasing the amount would not bring any 
significant added value. As noted in the pH determination, PLGA 1 degrades the 
fastest. This can now again be proven with the highest transfection efficiency. The 
faster the polymer degrades, the more siRNA lipoplexes are released for transfection, 
as proven in other studies [133, 184]. The long-term experiment to determine the 
transfection efficiency showed that up to the end of the test on day 20 where an uptake 
of the siRNA AF 488 had taken place. Within the first two days, the efficiency was very 
high and reached the highest level with the PLGA 1 coating at 96%. Such a burst 
release is seen as a positive effect in the transfection of cells, as this affects the 
effectiveness for a long-term gene silencing. A phase with decreasing uptake of siRNA 
NPs from day 3 to 6 followed and from day 7 to 20 a phase with progressively low 
uptake of siRNA NPs. The results suggest that the developed PLGA multilayer coating 
is a promising approach for a stent coating to release an active agent over a period of 
time. 
In addition, co-transfection with an eGFPmRNA and siRNA AF 555 was achieved with 
the multilayer PLGA construction. To our knowledge, this is the first time that cells have 
been transfected with both siRNA and mRNA. This proves that it is possible to include 
active ingredients in different layers of the multilayer system and to deliver them 
simultaneously. Furthermore, this shows that EA.hy926 and possibly cells in general 
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are able to control two opposing mechanisms in protein expression by external 
intervention. 
The PLGA coatings were tested for the release of lipoplexes with siICAM–1 and thus 
for the potential of gene silencing. Once again PLGA 1 coating was the most effective 
as it reduced ICAM–1 expression of EA.hy926 with 64% the most. Although PLGA 2 
and 3 significantly reduced ICAM–1 expression, they did not reduce it as much as 
PLGA 1. The results of the primary hVECs showed reduced but not significant reduced 
ICAM–1 expression levels after transfection with the siICAM–1 integrated lipoplexes in 
the PLGA layers compared to EA.hy926. This result is consistent with the literature, as 
it is also described here that primary cells are generally more difficult to transfect [185, 
186]. The correct cleavage site of ICAM–1 was confirmed by 5`-RLM RACE PCR after 
siICAM–1 transfection. In summary, the PLGA 1 coating with integrated lipoplexes is 
a promising approach for stent therapy of arteriosclerosis. 
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3.3 Local gene silencing of ICAM–1 by polyelectrolyte multilayer coating of 
hyaluronic acid and poly(ethylenimine) 
Due to their complex structure, PEMs are excellently suited for embedding active 
ingredients and releasing them in the system. The structure with oppositely charged 
polymers is stable due to the electrostatic interactions. The transfection agent PEI is 
very well suited for a PEM construction, because it can complex the siRNA and 
mediates transfection. Moreover, with its positive charge it can bind with a negatively 
charged polymer, such as HA. The aim of the study was to develop a PEM system with 
integrated siRNA polyplexes for substrate-mediated gene silencing of ICAM–1. The 
multilayer build-up of HA and PEI with complexed siRNA took place with two different 
coating methods (dipping and drying) and showed that the modified system (drying) 
yields the desired success in gene silencing. The dipping method for PEM build-up did 
not cause significant reduction of the adhesion molecule ICAM–1 with 
PEI(HA/PEI)2(HA/PEI-siRNA)3,10 and 1.5 µg siICAM–1 and 5 µg siICAM–1, 
respectively. The modified LbL technique, in which the HA layers and the polyplex 
layers were alternately dried by air drying, resulted in a significant reduction of ICAM–
1. The highest reduction of 44.4% remaining ICAM–1 adhesion molecule was achieved 
with 10 bilayers and the lowest reduction of 74.0% with 3 bilayers. The transfection 
efficiency test underlined the effectiveness of the air drying method, where 50.3% cells 
were transfected by 10 bilayers in comparison to 3 bilayers with 21.1% transfected 
cells. These results suggest that the dipping time of 10 minutes may not be sufficient 
for the required amount of polyplexes to bind to the HA layer. In another study, the dip 
and wash method used a dip time of 2 h for DNA lipoplexes with glycol-chitosan and 
HA layers. Both cell types, NIH3T3 and HEK293, were successfully transfected [129]. 
The drying method allowed effective application of the HA and polyplex layers. It is 
advantageous that the amount of siRNA dried up can be determined precisely, since 
liquid is not left over like during dipping. The results of transfection efficiency and gene 
silencing also demonstrate that the amount of 5 μg siRNA makes a significant 
difference, as was the case in our previous studies [179, 187]. The gene silencing 
experiment was performed with 3, 5, 7, 10, and 12 bilayers and all bilayers showed a 
significant reduction of ICAM–1 as a function of the number of layers. With increasing 
number of layers and thus also the amount of siRNA, the reduction of ICAM–1 up to 
the tenth double layer became higher. The 12 bilayers showed no further reduction of 
ICAM–1 and the value was slightly higher than that of 10 bilayers. Even a significant 
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increase in the bilayers to 24 did not yield any higher reduction of ICAM–1. This leads 
to the assumption that EA.hy926 from a siICAM–1 amount of 5 μg are already 
saturated and do not take up any further siRNA in the cell or that the PEM structure 
has reached its maximum after 10 bilayers. The successful bilayer construction of HA 
and the polyplexes was confirmed in the gene silencing experiment and further 
underpinned by scanning the different bilayer platelets for fluorescence intensity. As 
the bilayers increased, so did the intensity. The drying method thus shows the 
controlled assembly and incorporation of the bilayers and the siRNAf. 
The release experiment showed a rapid release of the siRNAf particles from all bilayers 
(3, 5, 7, and 10). Within the first hour almost all of the siRNAf was released from all 
bilayers and the subsequent measurement times after 4, 24 and 48 h showed 
comparable values to the controls. Thus, the fast release of siRNAf during the first hour 
is responsible for the high transfection efficiency and gene silencing of ICAM–1. As 
shown in previous studies, such a burst release is responsible for a very high efficiency 
of gene transfection and especially gene silencing [178, 179, 187]. Evidence of rapid 
release of polyplexes also revealed that the re-cultivation of the 10 and 24 double-
layered PEMs could not achieve gene silencing of ICAM–1 after renewed 24 h 
cultivation. The release time of polyplexes from the PEMs is of particular importance 
for use in the field of atherosclerosis therapy. Depending on how fast the particles are 
released and the cells transfected, coatings can be used differently. For example, a 
rapid-release coating system may employ the use of a balloon catheter, which briefly 
expands the atherosclerotic narrowed artery and transfects cells at the same time. An 
advantage of this therapy is that no foreign body remains in the vessel, which could 
cause a defense reaction of the body. Furthermore, drug eluting balloons are promising 
in the therapy of coronary interventions including ISR as shown in many studies with 
paclitaxel or sirolimus [188-190]. 
Although in our experiments the reverse assay was used for the transfection 
experiments, viability of the cells is important for successful transfection. The multilayer 
structure of HA and the polyplexes is better tolerated in terms of viability for the 
EA.hy926 cells than a monolayer of the polyplexes. The cell numbers of the multilayer 
coatings with 10 bilayer siICAM–1 or siSCR were both significantly higher than the 
comparable samples with the monolayer. The HA had a positive effect on the cell 
number and seems to have a protective effect on the cells. Similarly, one study showed 
that the combination of HA and PEI has less toxic effects on the cells than PEI alone 
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[98]. High molecular weight HA which was used in our and Han’s study is credited with 
an anti-inflammatory effect [191]. 
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4 Future perspectives 
The current interventional therapy in the treatment of arteriosclerosis is seeking new 
approaches to reduce the rate of restenosis following stent implantation. Many new 
approaches are being investigated which have the potential to release drug-eluting 
substances from substrates to effect endothelial healing or re-endothelialization. 
With this thesis, three different bioactive coatings with siICAM–1 have been developed 
that can improve the outcome of atherosclerotic interventional therapy with a stent or 
balloon catheter. Since not only ICAM–1 as one adhesion molecule is responsible for 
the leukocyte-adhesion molecule cascade; several other adhesion molecules like E-
selectin, P-selectin, VCAM–1 and PECAM–1 should be tested. In addition, it could 
investigate how simultaneous transfection with a cocktail of the siRNAs of the above-
mentioned adhesion molecules affects the respective gene expressions. Furthermore, 
the promising co-transfection of ICAM–1 and eGFPmRNA should be further 
investigated with a functional mRNA. The insertion of the natural anti-platelet protein 
CD39 as mRNA could increase gene expression and thus counteract thrombosis which 
was already described in our group. This is a promising approach in stent therapy, as 
on the one hand oral antiplatelet therapy can act locally and on the other hand the risk 
of ISR is reduced. For the desired re-endothelialization of the stent area, the anti-CD34 
antibody could also be integrated into the long-term coatings. This can bind the 
endothelial progenitor cells from the blood, which then differentiate into ECs and 
prevent thrombosis from developing. The emergence of the rapid progression of 
atherosclerosis is a multifactorial process, which is why many more types of 
intervention are possible, such as the suppression of smooth muscle cell proliferation 
or growth factors. 
Further, in vivo experiments are needed to test the effect of long-term release with 
PLGA and ATCOL coatings. Likewise, this should also be checked with the fast-
release HA/PEI coating. The in vivo experiments with atherosclerotic vessels might 
also provide information on how long a release and transfection with the applied ICAM–
1 siRNA is needed to prevent the unwanted leucocyte adhesion. If a longer release for 
stent therapy is evident, further intermediate layers of slowly degradable PLGA could 
be incorporated in the PLGA multilayer structure. Similarly, in the case of the ATCOL 
coating, a capping layer of a polymer could be applied so that the release of the siRNA 
takes place with a delay. This multifactorial approach of different siRNAs and mRNAs 
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to improve the healing and reduction of restenosis of stents or balloons leads to a 
personalized and especially by the specific processes, low-side-effect therapy which 
could be of great benefit especially in view of aging society. 
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6 Appendix 
6.1 Own contribution 
Publication I 
An Atelocollagen Coating for Efficient Local Gene Silencing by Using Small Interfering 
RNA 
All experiments reported in this publication were planned, performed and evaluated by 
myself. Dimitrios Nothdurft was involved in the experimental procedure. The ELISAs 
for the hemocompatibility test were performed by Julia Kurz and Ilka Degenkolbe 
performed the hemolysis assay. The manuscript was written by myself and Andrea 
Nolte revised the manuscript. Andrea Nolte was intensively involved in the planning of 
this study. 
 
Publication II 
RNA-Eluting Surfaces for the Modulation of Gene Expression as A Novel Stent 
Concept 
All experiments reported in this publication were equally planned, performed and 
evaluated by Diane Zengerle and myself. Andreas Behring and Meltem Avci-Adali 
provided the mRNA. Julia Kurz supported the ELISA performance for the 
hemocompatibility test. Susanne Hossfeld conducted the 5’-RLM-RACE-PCR 
experiments. The results of the experiments were statistically evaluated by Diane 
Zengerle. The manuscript was written by myself and Andrea Nolte revised the 
manuscript. Andrea Nolte was intensively involved in the planning of this study. 
 
Publication III 
Hyaluronic acid/poly(ethylenimine) polyelectrolyte multilayer coatings for siRNA-
mediated local gene silencing 
All experiments reported in this publication were planned, performed and evaluated by 
myself. Bernd Neumann was involved in the experimental coating procedure. The 
manuscript was written by myself and Hans Peter Wendel and Andrea Nolte revised 
the manuscript. Andrea Nolte was intensively involved in the planning of this study. 
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RNA-Eluting Surfaces for the Modulation of Gene Expression as A Novel Stent 
Concept 
  
Appendix  67 
Appendix  68 
Appendix  69 
Appendix  70 
Appendix  71 
Appendix  72 
Appendix  73 
Appendix  74 
Appendix  75 
Appendix  76 
Appendix  77 
Appendix  78 
Appendix  79 
Appendix  80 
Appendix  81 
Appendix  82 
Appendix  83 
Appendix  84 
Appendix  85 
Appendix  86 
  
Appendix  87 
6.4 Publication III 
Hyaluronic acid/poly(ethylenimine) polyelectrolyte multilayer coatings for siRNA-
mediated local gene silencing 
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6.5 List of abbreviations 
5’-RLM-RACE-PCR 5´-RNA ligase mediated rapid amplification of cDNA-ends 
PCR 
ACE    angiotensin-converting enzyme 
AF    Alexa Fluor 
Ago2    Argonaute protein 2 
ALS    amyotrophic lateral sclerosis 
apoB    apolipoprotein B 
ATCOL   Atelocollagen 
ATP    adenosine triphosphate 
BMS    bare metal stent 
bp    base pair 
 C    degree Celsius 
CABG    coronary artery bypass surgery 
CAD    coronary artery disease 
CAM    cellular adhesion molecule 
cDNA    copy deoxyribonucleic acid 
CHD    coronary heart disease 
CVD    cardiovascular disease 
CXCL    chemokine ligand 
Da    Dalton 
DES    drug-eluting stent 
DMEM   Dulbecco’s Modified Eagle Medium 
DOPE    1,2-dioleoyl-sn-glycero-3-phosphoetanolamine 
DOSPA 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-
dimethyl-1-propanaminium trifluoroacetate 
dsRNA   double stranded ribonucleic acid 
EC    endothelial cell 
ECM    extracellular matrix 
eGFP    enhanced green fluorescent protein 
eNOS    endothelial nitric oxide synthase 
ESAM    endothelial cell specific adhesion molecule 
ESC/EACTS European Society of Cardiology/ European Association for 
Cardio-Thoracic Surgery 
FDA    Food and Drug Administration 
h    hour 
HA    hyaluronic acid 
HBV    hepatitis B virus 
HIV    human immunodeficiency virus 
hVECs   human vascular endothelial cells 
ICAM–1   intercellular adhesion molecule–1 
IL–1    Interleukin–1 
IL–6    Interleukin–6 
ISR    in-stent restenosis 
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JAM    junctional adhesion molecule 
K    kilo 
KHK    koronare Herzkrankheit 
LbL    layer-by-layer 
LDL    low-density lipoprotein 
LFA1    lymphocyte function-associated antigen 1 
LOX–1   lectin-like receptor–1 
m    milli 
M    molar 
MAC1    macrophage–1 antigen 
MADCAM1   mucosal vascular addressin cell adhesion molecule 1 
MCP–1   monocyte chemoattractant protein–1 
M-CSF   macrophage colony-stimulating factor 
min    minute 
miRNA   micro RNA 
MMP    matrix metalloproteinase 
mRNA   messenger ribonucleic acid 
N/P    nitrogen/phosphate 
NF-κB    nuclear factor k-light-chain-enhancer of activated B cells 
NO    nitric oxide 
NOX2    NADPH oxidase 2 
NP    nanoparticle 
nt    nucleotide 
OAS    2'-5'-oligoadenylate synthetase 
oxLDL   oxidized LDL 
PBS    phosphate buffered saline 
PCI    percutaneous coronary intervention 
PCR    polymerase chain reaction 
PCSK–9   proprotein convertase subtilisin/kexin type–9 inhibitor 
PECAM–1   platelet/endothelial-cell adhesion molecule–1 
PEG    poly(ethylene glycol) 
PEI    poly(ethylenimine) 
PEM    polyelectrolyte multilayer 
PGA    poly glycolic acid 
PI3K    phosphoinositide 3–kinase 
PLA    poly lactic acid 
PLGA    poly(lactic-co-glycolic acid) 
PMN    polymorphonuclear granulocyte 
PSGL–1   P-selectin glycoprotein ligand–1 
PTCA    percutaneous transluminal coronary angioplasty 
qRT-PCR   quantitative Real-Time PCR 
RGD    arginine-glycine-aspartate 
RISC    ribonucleic acid induced silencing complex 
RNA    ribonucleic acid 
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RNAi    ribonucleic acid interference 
SC5b9   serum complement membrane attack complex 
scrRNA   scrambled RNA 
siRNA    small interfering ribonucleic acid 
siSCR    small interfering scrambled RNA 
SMC    smooth muscle cell 
SOD    superoxide dismutase 
STAT1   signal transducers and activators of transcription 1 
TAT    thrombin-antithrombin III-complex 
TNF-α    tumor necrosis factor-α 
VCAM–1   vascular cell adhesion molecule–1 
VE-cadherin   vascular endothelial cadherin  
VLA4    very late antigen 4 
VSMC   vascular smooth muscle cell 
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